Risk factors for antidepressant-related switch to mania

Journal of Clinical Psychiatry

Volumn 73, Issue 2, 2012, Pages

  Valentí, Marc ^a   Pacchiarotti, Isabella ^a   Bonnín, C Mar ^a   Rosa, Adriane R ^a   Popovic, Dina ^a   Nivoli, Alessandra M A ^a   Goikolea, José Manuel ^a   Murru, Andrea ^a   Undurraga, Juan ^a   Colom, Francesc ^a   Vieta, Eduard ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; LAMOTRIGINE; LITHIUM SALT; MOOD STABILIZER; OXCARBAZEPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ADULT; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BIPOLAR MANIA; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG RESPONSE; FEMALE; HUMAN; HYPOMANIA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIXED MANIA AND DEPRESSION; ONSET AGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR;

EID: 84857693708     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.11m07166     Document Type: Article

References (36)

1. Rosa AR, Reinares M, Michalak EE, et al. Functional impairment and disability across mood states in bipolar disorder. Value Health. 2010; 13(8):984-988. doi:10.1/j.1524-473.2010.0768.x PubMed
2. Baldessarini RJ, Salvatore P, Khalsa HM, et al. Morbidity in 303 first-episode bipolar I disorder patients. Bipolar Disord. 2010;12(3):264-270. doi:10.1/j.139-5618.2010.0812.x PubMed
3. De Dios C, Ezquiaga E, García A, et al. Time spent with symptoms in a cohort of bipolar disorder outpatients in Spain: a prospective, 18-month follow-up study. J Affect Disord. 2010;125(1-3):74-81. doi:10.1016/j.jad.209.12. 06 PubMed
4. Baldessarini RJ, Vieta E, Calabrese JR, et al. Bipolar depression: overview and commentary. Harv Rev Psychiatry. 2010;18(3):143-157. doi:10.3109/10673210374795 PubMed
5. Harel EV, Levkovitz Y. Effectiveness and safety of adjunctive antidepressants in the treatment of bipolar depression: a review. Isr J Psychiatry Relat Sci. 2008;45(2):121-128. PubMed
6. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60(11):1079-1088. doi:10.101/archpsyc.60.1.1079 PubMed (Pubitemid 37429647)
7. Baldessarini R, Henk H, Sklar A, et al. Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence. Psychiatr Serv. 2008;59(10):1175-1183. doi:10.176/api.ps.59.10.175 PubMed
8. Rosa AR, Cruz N, Franco C, et al. Why do clinicians maintain antidepressants in some patients with acute mania? hints from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM), a large naturalistic study. J Clin Psychiatry. 2010;71(8): 1000-1006. doi:10.408/JCP.09m05026gre PubMed
9. Tondo L, Vázquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatr Scand. 2010;121(6):404-414. doi:10.1/j.160-047.209.01514.x PubMed
10. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002; 159(suppl):1-50. PubMed
11. Ghaemi SN, Rosenquist KJ, Ko JY, et al. Antidepressant treatment in bipolar versus unipolar depression. Am J Psychiatry. 2004;161(1): 163-165. doi:10.176/api.ajp.161.1.163 PubMed (Pubitemid 38419324)
12. Vieta E. Antidepressants in bipolar depression. Acta Psychiatr Scand. 2008;118(5):335-336. doi:10.1/j.160-047.208.0123.x PubMed
13. Henry C, Demotes-Mainard J. Avoiding drug-induced switching in patients with bipolar depression. Drug Saf. 2003;26(5):337-351. doi:10.2165/02018- 20326050-03 PubMed (Pubitemid 36433832)
14. Möller HJ, Grunze H. Have some guidelines for the treatment of acute bipolar depression gone too far in the restriction of antidepressants? Eur Arch Psychiatry Clin Neurosci. 2000;250(2):57-68. doi:10.107/s040607035 PubMed (Pubitemid 30326316)
15. Visser HM, Van Der Mast RC. Bipolar disorder, antidepressants and induction of hypomania or mania: a systematic review. World J Biol Psychiatry. 2005;6(4):231-241. doi:10.1080/15629705102985 PubMed
16. Goodwin GM, Anderson I, Arango C, et al. ECNP consensus meeting: Bipolar depression; March 2007; Nice, France. Eur Neuropsychopharmacol. 2008;18(7):535-549. doi:10.1016/j.euroneuro.208.03.03 PubMed
17. Licht RW, Gijsman H, Nolen WA, et al. Are antidepressants safe in the treatment of bipolar depression? A critical evaluation of their potential risk to induce switch into mania or cycle acceleration. Acta Psychiatr Scand. 2008;118(5):337-346. doi:10.1/j.160-047.208.01237.x PubMed
18. Goodwin GM; Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition - recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2009;23(4): 346-388. doi:10.17/ 02698109102919 PubMed
19. Vieta E. Terciarismo en Psiquiatría: El Programa de Trastornos Bipolares del "Clínic" de Barcelona. Rev Psiquiatr Salud Mental (Barc). 2011;4(1): 1-4. doi:10.1016/j.rpsm.201.01.02
20. Vieta E. Bipolar units and programmes: are they really needed? World Psychiatry. 2011;10:2. PubMed
21. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6(4):278-296. doi:10.1/j.204-8260.1967.tb0530.x PubMed
22. Tohen M, Frank E, Bowden CL, et al. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord. 2009;11(5): 453-473. doi:10.1/j.139-5618. 209.0726.x PubMed
23. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133(5):429-435. doi:10.192/bjp.13.5.429 PubMed (Pubitemid 9006756)
24. First MB, Spitzer R, Gibbon M. Structured Clinical Interview for DSM-IV Axis I Disorders. Washington, DC: American Psychiatric Press Inc.; 1997a.
25. First MB, Spitzer R, Gibbon M. Structured Clinical Interview for DSM-IV Axis II Personality Disorders. Washington, DC: American Psychiatric Press Inc.; 1997b.
26. Bobes J, Bulbena A, Luque A, et al Grupo de Validacion en Espanol de Escalas Psicometricas. [A comparative psychometric study of the Spanish versions with 6, 17, and 21 items of the Hamilton Depression Rating Scale]. Med Clin (Barc). 2003;120(18):693-700. PubMed doi:10.157/13047695
27. Colom F, Vieta E, Martínez-Arán A, et al. [Spanish version of a scale for the assessment of mania: validity and reliability of the Young Mania Rating Scale]. Med Clin (Barc). 2002;119(10):366-371. PubMed
28. Colom F, Vieta E, Daban C, et al. Clinical and therapeutic implications of predominant polarity in bipolar disorder. J Affect Disord. 2006;93(1-3): 13-17. doi:10.1016/j.jad.206.01.032 PubMed (Pubitemid 43816068)
29. Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry. 1994;164(4):549-550. doi:10.192/bjp.164.4.549 PubMed (Pubitemid 24141686)
30. Vieta E, Martinez-Arán A, Goikolea JM, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry. 2002; 63(6):508-512. doi:10.408/JCP.v63n0607 PubMed (Pubitemid 34680359)
31. Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry. 2006;189(2):124-131. doi:10.192/bjp.bp.105.013045 PubMed (Pubitemid 44231270)
32. Leverich GS, Altshuler LL, Frye MA, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry. 2006;163(2):232-239. doi:10.176/api.ajp.163. 2.232 PubMed (Pubitemid 44480842)
33. Mazzarini L, Colom F, Pacchiarotti I, et al. Psychotic versus nonpsychotic bipolar II disorder. J Affect Disord. 2010;126(1-2):55-60. doi:10.1016/j.jad.2010.03.028 PubMed
34. Perlis RH, Ostacher MJ, Goldberg JF, et al. Transition to mania during treatment of bipolar depression. Neuropsychopharmacology. 2010;35(13): 2545-2552. doi:10.1038/np.2010.12 PubMed
35. Ghaemi SN, Ostacher MM, El-Mallakh RS, et al. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry. 2010; 71(4):372-380. doi:10.408/JCP.08m04909gre PubMed
36. McElroy SL, Weisler RH, Chang W, et al; EMBOLDEN II (Trial D1447C00134) Investigators. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010;71(2):163-174. doi:10.408/JCP.08m04942gre PubMed